Company Information
CIN
Status
Date of Incorporation
18 November 1977
State / ROC
Mumbai / ROC Mumbai
Last Balance Sheet
31 March 2023
Last Annual Meeting
29 September 2023
Paid Up Capital
282,168,156
Authorised Capital
2,770,000,000
Directors
Vijayalakshmi Iyer
Director/Designated Partner
over 2 years ago
over 2 years ago
Glenn Mario Saldanha
Director/Designated Partner
over 2 years ago
over 2 years ago
V S Mani
Director/Designated Partner
over 2 years ago
over 2 years ago
Cherylann Maria Pinto
Director/Designated Partner
over 2 years ago
over 2 years ago
Blanche Saldanha Elizabeth
Director/Designated Partner
over 2 years ago
over 2 years ago
Devendra Raj Mehta
Director/Designated Partner
over 2 years ago
over 2 years ago
Rajesh Vasudeo Desai
Director/Designated Partner
over 2 years ago
over 2 years ago
Dipankar Bhattacharjee
Director/Designated Partner
about 5 years ago
about 5 years ago
Sona Saira Ramasastry
Director/Designated Partner
about 6 years ago
about 6 years ago
Brian William Tempest
Director/Designated Partner
over 13 years ago
over 13 years ago
Sridhar Gorthi
Director/Designated Partner
over 20 years ago
over 20 years ago
Past Directors
Murali Neelakantan
Whole Time Director
about 8 years ago
about 8 years ago
Padmanabhan Ganesh
Cfo(kmp)
over 9 years ago
over 9 years ago
Bernard Hubert Munos
Additional Director
almost 14 years ago
almost 14 years ago
Hocine Sidi Said
Director
about 15 years ago
about 15 years ago
Marshall Joseph Mendonza
Company Secretary
almost 17 years ago
almost 17 years ago
Mahadevan Gopal Krishnan
Director
over 22 years ago
over 22 years ago
Natvarlal Bhimbhai Desai
Director
over 22 years ago
over 22 years ago
Abhinna Mohanty Sundar
Whole Time Director
over 23 years ago
over 23 years ago
Julio Francis Ribeiro
Director
over 26 years ago
over 26 years ago
Gracias Anthony Saldanha
Director
about 48 years ago
about 48 years ago
Patents
The present invention relates to extended release pharmaceutical compositions of Topiramate or a salt thereof. The invention also relates to processes for the preparation of such compositions and use thereof for treatment of seizures.
The present patent application relates to a process for the isolation and purification of a proanthocyanidin polymeric composition the composition having high purity and being suitable for use in pharmaceutically effective formulations. In particular the invention relates to a process for the production of Crofele...
The present patent application relates to a method of treating allergic rhinitis in a subject (preferably a human) by administering a combination of mometasone or its salt and olopatadine or its salt.
A twin action antipityrosporal shampoo comprising concomitant actives ketoconazole and zinc pyrithione in combination with pharmaceutically acceptable excipients and a method of making the same. The shampoo comprises ketoconazole upto 2% by weight and zinc pyrithione upto 1% by weight.The method comprises mixing ket...
The present invention provides oxalate salts of teneligliptin and solvates thereof exhibiting superior physiochemical properties. In particular, crystalline form of teneligliptin 2.5 oxalate 1.0 hydrate and crystalline form of teneligliptin 3.0 oxalate 1.0 hydrate are disclosed. Also provided are methods of preparin...
An oral pharmaceutical composition in a solid dosage form comprising (a) a core
comprising a therapeutically effective amount of at least one acid labile, substituted
benzimidazole H+/K+-ATPase proton pump inhibitor; and (b) an enteric coating on at least a portion of the core, wherein the composition provides a d...
The present invention relates to a process for the preparation of macitentan.
The present invention relates to a breath actuated dry powder inhaler wherein a breath actuated mechanism comprises a flap (11) movable from a substantially closed position to a substantially open position and a bistable biasing spring (10) holding the flap in the substantially closed position. The breath actuated m...
A process for preparing Form II crystals of clarithromycin is provided comprising(a) treating clarithromycin with a carboxylic acid in an organic solvent to provide a clarithromycin acid salt; and, (b) heating the clarithromycin acid salt under vacuum and at a temperature capable of providing Form II crystals of cla...
The present invention is directed to a solid oral controlled release pharmaceutical -
composition suitable for once-a-day administration, comprising - a., therapeutically
effective amount of a pharmaceutical^ active ingredient erythromycin or a derivative.. -
thereof, a release retardant complex and oth...
A controlled release, solid, oral pharmaceutical composition comprising a methylxanthine, preferably, theophylline or its pharmaceutically acceptable salts, and having water/moisture content less than 4% by weight of the composition. The controlled release, solid, oral pharmaceutical composition of methylxanthine is...
An aldosterone antagonist such as eplerenone having a particle size of less than about 25 microns and greater than 15 micron is provided. Also provided a process for preparing same pharmaceutical composition for the same.
The present invention relates to a process for the preparation of ospemifene and pharmaceutically acceptable salts thereof which comprises the step of recycling the undesired E-4-(4-hydroxy-1,2-diphenylbut-1-enyl)phenol to generate an isomeric mixture of Z,E-4-(4-hydroxy-1,2-diphenylbut-1-enyl)phenol.
...
The present invention relates to process for preparation of tavaborole with high
purity.
The present invention relates to method of assessing the purity of tavaborole.
The present invention relates to pharmaceutical compositions comprising Azelnidipine. Further the present invention also relates to a fixed dose pharmaceutical combination of Azelnidipine with a beta-blocker such as Metoprolol.
The present invention relates to a stable fixed dose aqueous pharmaceutical composition (e.g. contained in a container) for nasal administration to a human comprising mometasone or its salt olopatadine or its salt. The composition may further include a hydrocolloid. The invention also relates to a process for prepar...
The present invention relates to novel crystalline forms of lomitapide mesylate and process for preparation thereof.
The present invention relates to process for the preparation of azilsartan.
The present invention relates to a stable topical formulation comprising an effective amount of voriconazole or its pharmaceutically acceptable salt, and at least a pharmaceutical carrier; a process for preparing the same and use of such formulation for the treatment of local or non-systemic fungal infections in a s...
ABSTRACT
The present invention relates to a process for the preparation of ledipasvir a compound of formula I, which is useful as an antiviral agent. The present invention also provides ledipasvir phosphate.
To,
The Controller of Patents
The Patent Office Branch, Mumbai
...
The present invention relates to a pre-lyophilized composition comprising bendamustine or its pharmaceutically acceptable salt, a pharmaceutically acceptable carrier, an organic solvent and water. Furthermore, the present invention provides a stable pharmaceutical composition comprising bendamustine hydrochloride pr...
The present invention relates to an improved process for the preparation of compound of formula Int-A and Teneligliptin, 3-{(2S,4S)-4-[4-(3-methyl-1-phenyl-5-pyrazolyl)-1-piperazinyl]-2-pyrrolidinylcarbonyl}-1,3-thiazolidine and pharmaceutically acceptable salts or hydrates thereof.
The present invention relates to teneligliptin process for preparation thereof and pharmaceutical compositions of teneligliptin.
The present invention relates to a process for the preparation of canagliflozin and intermediates thereof.
The present invention relates to a process for the preparation of amorphous dapagliflozin. The present invention relates to 2,3-butanediol solvate of dapagliflozin and process for its preparation.
The present invention relates to topical pharmaceutical compositions comprising fusidic acid and a corticosteroid. More particularly, the present invention relates to topical pharmaceutical compositions comprising fusidic acid and mometasone or halobetasol or their esters, processes for preparing the same, and the u...
The present invention relates to a nanoparticulate pharmaceutical composition comprising aprepitant and at least one surface stabilizer and a method for preparing such composition. The invention is further directed to a pharmaceutical dosage form comprising a nanoparticulate pharmaceutical composition of aprepitant,...
The present invention relates to novel ivabradine cyclamate salt and process for the preparation thereof.
The present invention relates to an improved process for the preparation of arformoterol !.-(+)- tartrate. More specifically the present invention relates to a novel process for the preparation of arformoterol L-(+)- tartrate via arformoterol D-(-)-tartrate.
The present invention relates to novel amorphous form of lomitapide mesylate salt and process for preparation thereof.
The present invention relates to a process for preparation of apremilast. The present invention relates to p-xylene solvate of apremilast and process for its preparation.
To,
The Controller of Patents
The Patent Office Branch, Mumbai
The present invention relates to process for preparing azelaic acid.
The present invention relates to process for the preparation of vortioxetine hydrobromide.
ABSTRACT OF THE INVENTION
The present invention relates to a process for the preparation of amorphous lumacaftor. The present invention relates to a process for the preparation of intermediate 6-amino-2-halo-3-methylpyridine compounds used in the preparation of lumacaftor. The present invention relates to lumacafto...
ABSTRACT OF THE INVENTION
The present invention relates to a process for the preparation of pirfenidone.
The present invention relates to non-enteric pharmaceutical composition for oral administration comprising crofelemer and a pharmaceutically acceptable excipient; a process for preparing such composition; and its use in treating secretory diarrhea in a subject.
The present invention provides process for the preparation of teneligliptin via intermediates compounds of formula 29 and 32.
The present invention relates to a process for the preparation of luliconazole and salts thereof.
The present invention relates to an inhaler device with dose counter means. Particularly, the present invention relates to a pressurized metered dose inhaler for inhalation of medication by a patient, wherein the inhaler has dose counter means. The metered dose inhaler can be used to deliver medication for the treat...
The present invention relates to a pharmaceutical powder composition for inhalation comprising an active ingredient and a pharmaceutically acceptable carrier process for preparing such composition and its use for the treatment of respiratory disorder in a subject.
Novel palonosetron free base in an amorphous form and crystalline form-G and processes for their preparation are disclosed. Process for the preparation of palonosetron hydrochloride from the novel free base of palonosetron are also disclosed.
The present invention relates to a fixed dose pharmaceutical composition comprising mometasone and azelastine. Particularly, the present invention provides a stable fixed dose pharmaceutical composition in the form of a nasal spray comprising mometasone or its salt and azelastine or its salt; a process for preparing...
Improved processes for the preparation of 3-hydroxy-3-methylglutaryl-coenzyme A
(HMG-CoA) inhibitors, e.g., simvastatin, and their intermediates are provided. In one
embodiment, a process for the preparation of a carboxylic acid amine salt of formula I is
provided
wherein R and R are as def...
Solvates of lornoxicam are provided . Also provided are processes for their preparation and pharmaceutical compositions containing same.
A pharmaceutical cream composition is provided comprising (a) a therapeutically effective amount of one more active pharmaceutical ingredient comprising one or more macrolide related immunosuppressants or pharmaceutically acceptable salts or esters thereof; (b) one or more cream forming agents; and (c) one or more s...
A pharmaceutical gel composition is provided comprising (a) a therapeutically effective amount of one or more active pharmaceutical ingredient comprising one or more macrolide related immunosuppressants or pharmaceutically acceptable salts or esters thereof;(b) one or more gel forming agents; and (c) one or more ski...
A process for preparation of a biphenyl containing compound of genral
formula I:
wherein R1 is a C3-6 carbonyl containing compound; R2 is a C3-6 substituted or unsubstituted, stright or branched alkyl group, or R1 and R2 together with the vitrogen atom to which they are bonded are joined together to form a s...
A pharmaceutical ointment composition is provided comprising (a) a therapeutically effective amount of one or more active pharmaceutical ingredient comprising one or more macrolide related immunosuppressants or pharmaceutically acceptable salts or esters thereof; (b) an ointment base; and (c) one or more skin penetr...
A process for preparing perindopril is provided comprising condensing an N-[(S)-1-carbethoxybutyl]-(S)-alanyl halide of formula II: wherein Xis a halide with an (2S, 3aS, 7aS)-2-carboxyperhydroindole of formula III: wherein Ris hydrogen or a protecting group.
A process for preparing ezetimibe is disclosed comprising (a) reacting a ketone of formula III:
0
(III)
wherein R and R are as defined herein with an aromatic containing halide protecting group to provide an aromatic protected ketone of formula IV:
(IV);
(b) hydrolyzing the aromatic protected ketone of...
A process for producing fluvastatin or a pharmaceutically acceptable salt thereof in a substantially pure amorphous form is provided comprising (a) providing a solvent solution comprising substantially non-amorphous fluvastatin or a pharmaceutically acceptable salt thereof in a solvent capable of dissolving the fluv...
The present invention provides an improved process for the preparation of zonisamide or a derivative thereof comprising (a) reacting 1,2-benzisoxazole-3-methane-sulfonic acid with a halogenating agent in a first organic solvent to provide benzisoxazole methane sulfonyl halide; and (b) reacting benzisoxazole methane ...
A process for the preparation of a pyrrole derivative or a racemic mixture, an enantiomer a diastereoisomer, a mixture thereof, a tautomer thereof, or a pharmaceutically acceptable salt thereof reacting an amino compound of the general formula
wherein each R is independently hydrogen or a hydrolyzable protectin...
The present invention provides a novel intermediate of ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)ethylnyl] nicotinate and a for its preparation. The present invention also provides for the preparation of ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)ethylnyl] nicotinate of Formula I using the intermediate.
...
A process for preparation of cilazapril is provided comprising isolating an organic or inorganic acid salt of (1S, 9S) tert butyl 9 - [[(1S) ethoxycarbony1- 3 -phenylpropy1]amino] octahydro - 10 -oxo - 6H - pyridazino [1,2-a] [1,2] diazepine - 1 - carboxylate and (b) converting the organic or inorganic acid salt to ...
The present invention relates to novel compounds useful as dipeptidyl peptidase IV(DPP-IV) inhibitors of the formula:
wherein X,Y,a,R¹ and R² are as defined herein.
A Pharmaceutical composition containing sterol absorption inhibitors, such as ezetimibe and pharmaceutically acceptable salts thereof and a process for its preparation. The present invention provides a pharmaceutical composition comprising 90% of the particles of ezetimibe or its pharmaceutically acceptable salts no...
The present invention generally relates to a novel combination pharmaceutical composition of foam for topical administration, including, as the pharmaceutically active component one ingredient selected form the group of an antifungal agent and other ingredient selected form the group of steroidal anti-inflammatory a...
The present invention relates generally to a novel pharmaceutical composition
containing Dexibuprofen and paracetamol in the form of solid oral tablet dosage
form and process for making the same.
[0027] A process for the preparation of substantially pure acitretin of Formula I is
provided:
the process comprising (a) contacting a salt of acitretin with one or more solvents; and (b) isolating substantially pure acitretin from the product of step (a).
A process for the preparation of strontium ranelate or a hydrate thereof comprising reacting a tetraester compound of Formula II Wherein R, R₁, R₂, and R₃ are independently a linear or branched C₁-C6 alkyl group or a C₃-C₁₂ cyclic group, in the presence of a lithium base and in a solvent with an inorganic acid salt ...
A method for the preparation of amorphous esomeprazole in neutral form as well as composition, pharmaceutical compositions, and methods utilizing the amorphous form are described.
A taste-masking, pharmaceutical comosition is provided which comprises (a) a core comprising an active pharmaceutical igredient having a taste for which masking is desired and (b)a taste-masking film coating layer comprising (i) a film-forming, water insolube polymer and (2) a pH dependent, water insoluble polymer w...
Mifepristone substantially in polymorph form M is provided. Also provided is a process for the preparation of polymorph form M of mifepristone comprising the steps of (a) dissolving crude mifepristone in a polar solvent at an elevated temperature to obtain a clear solution; (b) cooling the solution to a temperature ...
Disclosed is a controlled release modifying complex for solid suitable comprises modifying excipients. The release modifying an auxiliary release thereof, wherein modifying agents effect and ingredient.oral controlled release pharmaceutical for an once-a-day administration. The active pharmaceutical ingredient, comp...
Crytalline forms of almotriptan and almotriptan malate are disclosed. Process for their preparation and pharmaceutical compositions containing the same are also disclosed. The amorphous form of almotriptan malate, processes for its preparation and pharmaceutical composition containing the same are also disclosed.
...
This invention relates to a multi-compartment container system and assembly for separately storing two or more components in individual containers until ready for combining and mixing prior to use. This invention further relates to a multi-compartment container that may be used to dispense a predetermined amount of ...
A pharmaceutical composition comprising a core having a film coating of hydrophilic polumer and an antifungal agent, and having a dissolution at 60 minutes greater than or equal to about 70%, as measured using the type II paddle method at 100 rpm according to the US pharmacopoeia, in a dissolution medium comprised o...
Rizatriptan benzoate in an amorphous form is disclosed. Also disclosed is a process for preparing rizatriptan benzoate substantially in amorphous form comprising the steps of (a) preparing a solvent solution comprising non-amorphous rizatriptan benzoate and one or more solvents capable of dissolving the non-amorphou...
THE PRESENT INCENTION IS DIRECTED TO A BILAYERED SUSTAINED TABLET COMPRISING ALFUZOSIN OR PHAMACEUTICALLY ACCEPTABLE SALT, SOLCATES, ENANTIOMERS OF MIXTURES THEROF, AND METHOD OF MANUFACTURING THE SAME. ONE OF THE LAYERS OF THE BILARED TABLET WOULD INCLUDE DRUG ALONG WITH A HYDROPHILIC POLYMER AND THE SECOND LAYER W...
Novel salts of rosuvastatin and process for their preparation are disclosed. Pharmaceutical composition comprising a therapeutically effective amount of one or more salts of rosuvastatin selected from the group consisting of a barium salt, strontium salt, zinc salt, cesium salt, cadmium salt and mixture thereof are ...
A topical pharmaceutical microsphere composition comprising an active ingredient such as adapalene in a suitable carrier is provided. There is also provided a method of treating acne by administering the said composition to the patient"s skin in need of treatment. Topical adapalene microsphere composition of the pre...
A topical pharmaceutical composition comprising Latanoprost or its pharmaceutically acceptable salts there of and a pharmaceutically acceptable carrier is provided. The present invention provides the pharmaceutical compositions for topical delivery of a medicament comprising Latanoprost for the treatment of vitiligo...
The present invention generally relates to a topical pharmaceutical composition of Voriconazole and a pharmaceutically acceptable carrier is provided, said composition being devoid of poloxamer. The composition is useful in the treatment of dermatophytic infections.
The present invention relates to a liposome composition comprising docetaxel or its pharmaceutically acceptable salt, and processes for preparing the same. Particularly, the present invention relates to a liposome composition for parenteral administration comprising docetaxel and a lipid, wherein said liposome compo...
The present invention relates to a novel polymorphic Form of aprepitant, a process for its preparation, pharmaceutical compositions and a method of treating nausea.
A process for the preparation of a compound of Formula III:
(III)
wherein X is a halide and Z is a protecting group, the process comprising reacting a 3,5-bis(l-cyano-l-methylethyl)benzyl halide with a 4-Z-l,2,4-triazole compound of the formula
wherein Z has the aforementioned meaning.
...
A process for purifying olmesartan medoxomil is provided comprising (a)
dissolving olmesartan medoxomil in a solvent system comprising a ketone and at least one solvent selected from the group consisting of an alcohol-containing solvent, an ester-containing solvent and mixtures thereof to obtain a solution; and (b)...
The present invention relates generally to a novel pharmaceutical combination of Amiloride and Torsemide. This invention also relates pharmaceutical composition comprising Amiloride and Torsemide for the treatment of congestive heart failure and process for preparation of the same.
The present invention relates to a topical composition comprising tacrolimus and a pharmaceutically acceptable solvent. Particularly, the present invention relates to a stable topical composition comprising tacrolimus and dimethyl isosorbide.
A high drug content oral solid dosage form is provided comprising about 50 mg to about 800 mg oxazolidinone or a pharmaceutically acceptable salt, hydrate or crystalline form thereof and one or more water soluble excipients.
A Strontium salt of esomeprazole is provided. A process for preparing a strontium salt of esomeprazole is also provided comprising reacting esomeprazole free base or a sodium, potassium or lithium salt of esomeprazole with a strontium source in one or more solvents.
The present invention provides micronized particles of substantially pure telmisartan or a pharmaceutically acceptable salt, ester or derivative thereof. Also provided are pharmaceutical compositions containing the micronized particles of substantially pure tel isartan or a pharmaceutically acceptable salt, ester or...
An extended release pharmaceutical composition in solid dosage form is provided comprising a core comprising a therapeutically effective amount of venlafaxine or a pharmaceutically acceptable salt thereof and an extended released coating associated with the core, wherein the core provides an immediate release of ven...
The present invention relates to pharmaceutical composition for oral administration comprising prasugrel or its salt and triflusal, as well as to a process for preparation of such composition, and use of such composition for treating a platelet aggregation disorder in a subject.
The present invention relates generally to a novel pharmaceutical composition containing Dedxibuprofen and paracetamol in the form of solid oral tablet dosage form and process making the same.
The present invention relates to a novel pharmaceutical composition of Olanzapine orally disintegrating tablet using direct compression technique and process for making the same.
The present provides process for the preparation of novel intermediates of (S)- Pregabalin. The present invention also provides for the preparation of (S)-Pregabalin or a pharmaceutically acceptable salt or solvate thereof using the intermediates.
Pharmaceutical compositions suitable for the treatment of bacterial dermatological infections and processes for their preparation are provided. The pharmaceutical compositions can be a semisolid pharmaceutical composition comprising a therapeutically effective amount of at least one antiacne agent and at least one a...
A process for the preparation of (2S, 3aS, 7aS) perhydroindole-2-carboxylic acid is provided comprising (a) esterifying a cis-perhydroindole-2-carboxylic acid with a first alcohol of the formula ROH and a suitable free acid to provide the acid salt (AS) of Formula V: (b) reacting the acid salt of Formula V with a fi...
Stable topical pharmaceutical compositions comprising a therapeutically effective amount of mupirocin or a pharmaceutically acceptable salt or ester thereof and are one or more esters of a fatty acid are disclosed. Also disclosed are stable topical pharmaceutical compositions comprising a therapeutically effective a...
Ropinirole hydrochloride substantially free of impurities and a process for its preparation is provided. Pharmaceutical compositions containing the same are also provided.
The present invention provides a process for preparing a stable pharmaceutical formulation comprising (a) preparing a solution comprising a therapeutically effective amount of imiquimod or a pharmaceutically acceptable salt thereof and an agent selected from the group consists of linoleic acid, lactic acid and mixtu...
Present invention is directed to a substantially stable pharmaceutical composition of Ropinirole or salts thereof, wherein an unknown individual impurity is controlled below 0.15%, more preferably below 0.1%. The above said quantities of unknown impurities are calculated based on the dose of Ropinirole in each unit....
The present invention relates to pharmaceutical compositions comprising a combination of Clindamycin and Clotrimazole for vaginal use for the treatment of bacterial infections, fungal infections or mixed infections of the vagina. More specifically, the invention relates to a vaginal suppository comprising 100 mg of ...
A process for the preparation of 7-formyl-indole of the formulaI is described. Thus, the process comprises of : 1)Selective oxidation of one methyl group of 2-nitro-m-xylene of the formula 13 with chromium trioxide in the presence of acetic anhydride/sulfuric acid to afford 3-methyl-2-nitro-benzaldiacetate of the fo...
Stabilized pharmaceutical composition comprising a therapeutucally effective amount of one or more active pharmaceutical ingredients capable of degradation in a low pH environment and stabilizing effective amount of one or more amino-group containing monomeric compounds and/or amido-group containing monomeric compou...
The present invention relates to a hydrophilic controlled release oral formulation containing the muscle relaxant drug tizanidine. The formulation is useful in the treatment of painful and inflammatory conditions associated with skeletal muscle spasma.
The present inventions relates generally to a crystalline form (-)-[2-[4-[(4-Chloropheny1)-pheny1 methy1]-1-piperaziny1]ethoxy] acetic acide dihydrochloride, generically known as levocetirizine dihydrochloride, a process for it prepration and pharmaceutical compositions containing same.
A pharmaceutical topical sustained release pharmaceutical composition for the treatment of acne comprising Retinoids contained in microspheres to the site of absorption or action and the proces for preparing the same.
The present invention relates generally to improved topical pharmaceutical formulations, their uses and methods of manufacturing. Specifically, the present invention relates to improved topical cream formulations of Sertaconazole or its pharmaceutically acceptable salts there of.
The present invention relates to a process for the preparation of 2-[2-[4-[(4-chloro phenyl) phenyl methyl]-1-piperazinyl] ethoxy acetic acid.
The present invention provides a process for the preparation of Atovaquone in a pure polymorphic form characterized by an X-ray powder diffraction pattern with peaks at about 7.0, 9.7, 14.2, 14.8, 17.0, 19.2, 20.4, 22.1, 22.7, 26.9 and 28.7±0.2 degrees 2 theta comprising: a) providing a solution of atovaquone in ap...
The present invention relates to a stable self-emulsifying composition for oral administration comprising atorvastatin, and processes for preparing
the same.
The present invention provides novel compound and preparation of this compound. The present invention also provides process for the preparation of Darifenacin hydrobromide or a pharmaceutically acceptable salt or solvate thereof using this novel compound.
Abstract
A compound of general formula (I)
wherein:
R1 R2 and R3 may be same or different and are independently selected for each occurance from the groups consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstitued alkynyl, substituted or unsub...
The present invention relates to a topical pharmaceutical corrlposition comprising mupirocin and beclomethasone, processes for its preparation, and its use in the treatment of infected dermatoses caused by bacteria susceptible to mupirocin, ind in the treatment or prevention of secondary bacterial infections in pati...
The present invention provides novel heterocyclic compounds of the general formula (I),
RiY
(I)
wherein,
R1 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstitued alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cyc...
The invention is directed to an immediate release pharmaceutical composition involving surfactants which provided rapid dissolution of the low solubility drug such as lercanadipine or its pharmaceutically acceptable salts. The pharmaceutical composition of the present invention provides rapid release of an effective...
The present invention relates to pharmaceutical dosage forms which include an antifungal having poor solubility. The pharmaceutical dosage forms of the present invention further comprise non-spherical granules, which do not contain a coated core region and may be formed into pharmaceutically acceptable dosage forms....
The present invention relates to new dipeptidyl peptidase IV (DPP-IV) inhibitors of the formula (I), and their analogs, isomers, pharmaceutical compositions and therapeutic uses method of making the same.
wherein:
R1, R2 and R3 are independently selected for each occurrence from the groups consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstitued alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylakyl, substitut...
A process for the preparation of a novel crystalline polymorph of olmesartan medoxomil, designated Form G, is provided comprising the steps of (a) preparing a solution comprising olmesartan medoxomil and one or more solvents selected from the group consisting of a nitrile, alchol and mixtures thereof at a suitable t...
Pharmaceutical composition a therapeutically effective amount of micronized particles of cilostazol or pharmaceutically acceptable salts or esters thereof, wherein at least about 50% of the micronized cilostazol particles have an effective average particle size of less than about 10 microns is provided.
...
A process is provided comprising (a) providing a solution of linezolid in organic solvent having a boiling point of less than about 150ºC; (b) addition of an anti solvent having boiling point more than 50ºC and recovering linezolid.
A process for the preparation of pyrimidine derivatives comprising reacting a Wittig reagent of the general formula wherein R is an alkyl of from 1 to 10 carbon atoms, aryl or arylalkyl, R¹ is a substituted or unsubstituted hydrocarbon group, R² and R³ are the same or different and are hydrogen or a substituted or u...
The present invention relates to a novel process for the preparation of dimethyl fumarate.
The present invention generally relates to an improved process for the preparation of intermediates for ropinirole. More specifically, the present invention relates to an improved process for the preparation of the intermediate 2-methyl-3-nitro-phenylethyl-N,N-di-n-propyl amine and use thereof for the preparation of...
The present invention disclosed a novel potassium salt of esomeprazole in polymorph form X, which can be used in pharmaceutical compositions. The present invention further discloses a process for preparing a polymorph form X of esomeprazole potassium by dissolving esomeprazole neutral form in a first solvent, adding...
A process for the preparation of (6R,12aR)-2,3,6,7,12,12a-hexahydro-2methyl-6-(3,4-methylenedioxyphenyl)pyrazino[1’,2’;1,6]pyrido[3,4-b]indole-1,4-dion of Formula I: the process comprising cyclizing a cis-isomer of a compound of formula II: wherein X is a leaving group, in presence of base.
...
The present invention relates to a novel pahrmaceutical composition as solid dosage form comprising Desmopressin acetate as a therapeutically active ingredient, and method for manufacturing the same.
The present invention provides a process for the preparation of the rosuvastatin intermediates and their conversion or its rosuvastatin or its pharmaceutically acceptable salts thereof.
The present invention relates to a process for the preparation of Efinaconazole and salts thereof.
The present invention relates to a process for the preparation of amorphous ticagrelor. The present invention relates to dimethyl formamide solvate of ticagrelor and process for its preparation.
The present invention relates to process for the preparation of type I crystals of aripiprazole and aripiprazole conventional hydrate.
The present invention relates to process for the preparation of aclidiunium or intermediates thereof. More particularly, it relates to the preparation of aclidinium bromide.
The present invention relates to a novel process for the preparation of sofosbuvir and intermediates thereof.
Processes for producing pharmaceutical compositions containing a proanthocyanidin polymer useful for the treatment and prevention of various conditions are provided. The invention specifically relates to processes for producing pharmaceutical formulations of a proanthocyanidin polymer composition which has been isol...
The present invention relates to a novel pharmaceutical composition comprising combination product in the form soft gel capsule containing therapeutically effective amount of Dexibuprofen and Paracetamol.
The present invention relates to pharmaceutical composition comprising Fluocinolone acetonide. Particularly, the invention relates to an oil composition for topical administration comprising therapeutically effective amount of Fluocinolone acetonide, a process for preparing the stable pharmaceutical composition and ...
The present invention relates to an inhalable pharmaceutical composition comprising glycopyrronium or its salt. Preferably, the present invention relates to an inhalable powder composition comprising an effective amount of glycopyrronium or its salt and lactose; a process of preparing such composition and its use in...
ABSTRACT
The present invention relates to process for the preparation of Ospemifene.
To,
The Controller of Patents
The Patent Office Branch, Mumbai
ABSTRACT
“NOVEL POLYMORPH OF SOLRIAMFETOL AND SALT THEREOF”
The present invention relates to novel polymorph of solriamfetol and its hydrochloride. More particularly the present invention relates to process for the preparation of solriamfetol hydrochloride.
The present invention provides a stable pharmaceutical compositions comprising gabapentin enacarbil or pharmaceutically acceptable salts thereof and the process of preparation thereof. The invention also relates to the use of said pharmaceutical compositions for the treatment of restless legs syndrome or post herpet...
The present invention relates to pharmaceutically acceptable formulations comprising oxalate salts of Teneligliptin and solvates thereof. Also provided are combinations with biguanides and use of said pharmaceutically acceptable formulations for the management of glucose metabolism disorders
The present invention relates to a process for the preparation of deutetrabenazine.
ABSTRACT OF THE INVENTION
“PROCESS FOR PREPARATION OF DEUTETRABENAZINE AND SALT THEREOF”
The present invention relates to salts of deutetrabenazine and process for its preparation.
To,
The Controller of Patents
The Patent Office Branch, Mumbai
ABSTRACT OF THE INVENTION
“PROCESS FOR PREPARATION OF VALBENAZINE AND SALTS”
The present invention relates to crystalline valbenazine tosylate and process for its preparation.
To,
The Controller of Patents
The Patent Office Branch, Mumbai
The invention relates to a combination of remogliflozin or salt or ester thereof and DPP-IV inhibitor or salt thereof. In particular, the invention relates to a fixed dose pharmaceutical composition comprising a combination of remogliflozin or salt or ester thereof and DPP-IV inhibitor or salt thereof. Disclosed is ...
The present invention relates to an immediate release oral formulation of remogliflozin or pharmaceutically acceptable salts thereof administered in patients in need thereof, for the treatment of diabetes mellitus. The present invention further relates to a pharmaceutical formulation comprising synergistic combinati...
A compound of the general formula (I) and method for preparing and using the compound of formula (I).
The present invention relates to an anti-inflammatory & analgesic topical clear gel composition of valdecoxib & a process for the manufacture thereof.
A process for the preparation of the alpha crystalline form of perindopril erbumine of formula I: the process comprising:(a) forming a solution comprising perindopril erbumine of formula I in one or more ketones;(b) heating the solution to reflux; and(c) cooling the solution t...
The present invention relates to an inhaler device with dose counter means. Particularly, the present invention relates to a pressurized metered dose inhaler for inhalation of medication by a patient, wherein the inhaler has dose counter means. The metered dose inhaler can be used to deliver medication for the treat...
ABSTRACT
The present invention relates to amorphous mirabegron and process for its preparation.
Abstract
The present invention provides process for the preparation of isavuconazonium sulfate. The invention further discloses process for the preparation of isavuconazole.
To,
The Controller of Patents
The Patent Office Branch
ABSTRACT
The present invention provides a process for the purification of deoxycholic acid or salt thereof.
ABSTRACT
The present invention relates to process for the preparation of sacubitril.
The present invention relates to process for preparation of fosaprepitant dimeglumine.
ABSTRACT OF THE INVENTION
The present invention relates to process for the preparation of amorphous betrixaban maleate.
To,
The Controller of Patents
The Patent Office Branch, Mumbai
ABSTRACT OF THE INVENTION
The present invention relates to a process for the preparation of crisaborole.
The present invention relates to a process for the preparation of lifitegrast, a compound of formula I, the process comprising deprotecting a compound of formula III using a Lewis acid. The present invention also relates to lifitegrast organic amine salt, a compound of formula II, process for its preparation and con...
The present invention provides a process for the preparation of bilastine.
ABSTRACT
The present invention relates to a process for the preparation of nintedanib or salt thereof. The process comprising reacting compound of formula VI with acetic anhydride and triethyl ortho benzoate to obtain a compound of formula V; further reacting the compound of formula V with the compound of formula I...
ABSTRACT
CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION COMPRISING APREMILAST
Disclosed are a controlled release oral composition comprising apremilast or salt thereof, a compressibility agent, a polymer, a swelling agent, a floating agent, and a pharmacutically acceptable excipient for the treatment of psoriasis...
The invention relates to a process for the preparation of elagolix sodium, a compound of formula I, the process comprising reacting 5-iodo-2,4-dimethoxy-6-methyl pyrimidine with (2-fluoro-3-methoxyphenyl)boronic acid to form compound of formula XVII which is converted to the compound of formula XVI. The compound XVI...
The invention relates to a process for the preparation of tezacaftor or salt thereof. The process comprising reacting compound IV with the compound of formula III to obtain a compound of formula II. The compound of formula II is recrystallized to obtain solid, which is then deprotected to obtain tezacaftor, the comp...
ABSTRACT OF THE INVENTION
The present invention relates to process for the preparation of crystalline betrixaban maleate and crystalline betrixaban.
Abstract
A process for the preparation of isavuconazonium sulfate via N-Boc isavuconazonium chloride having a purity of atleast 95%.
The present invention relates to a process for the preparation of bilastine, a compound of formula I. The present invention relates to p-xylene solvate of bilastine and process for its preparation. The present invention relates to a process for the preparation of bilastine form 2 via p-xylene solvate of bilastine.
...
ABSTRACT
The present invention relates to solriamfetol or novel salt thereof and its process for preparation. More particularly the present invention relates to solriamfetol novel salts and further its use in the preparation of solriamfetol hydrochloride of formula Ia.
The invention relates to a process for the preparation of elagolix or salt thereof. The process comprising reacting compound of formula XI’ with the compound of formula X to obtain a compound of formula IX. The compound of formula IX is reacted with a compound of formula VI to obtain the compound of formula V. The d...
Abstract
Current invention provides a process for the preparation of Lasmiditan.
The present invention provides a process for elafibranor, the process comprising reacting compound of formula II or the compound of formula III with a compound of formula IV. The present invention also involve purification of elafibranor by reacting elafibranor with benzyl amine to form compound of formula IX and tr...
The present invention relates to stable topical compositions comprising Luliconazole. Further the present invention also relates to stable topical compositions comprising combination of luliconazole with a corticosteroid such as betamethasone or clobetasol. The compositions are free of an aliphatic alcohol and a ket...
ABSTRACT
PHARMACEUTICAL COMPOSITION COMPRISING REMOGLIFLOZIN OR SALT OR ESTER THEREOF
The present invention is an extended release pharmaceutical composition, comprising: an extended release component comprising remogliflozin or salt or ester thereof; and optionally, an immediate release component comprising r...
ABSTRACT OF THE INVENTION
The present invention relates to the process of the preparation of (S)-netarsudil or a salt thereof.
The present invention relates to a process for the preparation of lasmiditan, a compound of formula I, or pharmaceutically acceptable salts thereof, the process comprising reacting a compound of formula IX with N-methoxymethylamine or salt thereof to obtain a compound of formula VII; reacting the compound of formula...
The present invention relates to a medicinal aerosol composition for inhalation comprising glycopyrronium or its pharmaceutically acceptable salt and one or more pharmaceutically acceptable excipients. In particular, the present invention relates to an aerosol solution composition comprising glycopyrronium or its ph...
ABSTRACT
PHARMACEUTICAL COMPOSITION COMPRISING REMOGLIFLOZIN OR SALT OR ESTER THEREOF AND TENELIGLIPTIN OR SALT THEREOF
The invention relates to a fixed dose combination of remogliflozin or pharmaceutically acceptable salt or ester thereof and DPP-IV inhibitor or pharmaceutically acceptable salt thereof. In pa...
Abstract
AMORPHOUS FORM OF REMOGLIFLOZIN AND REMOGLIFLOZIN ETABONATE AND PROCESS FOR THE PREPARATION THEREOF
The invention relates to an amorphous form of Remogliflozin and amorphous Remogliflozin etabonate. Also relates to substantially pure amorphous Remogliflozin or amorphous Remogliflozin etabonate having ...
STABLE COMPOSITION OF PILOCARPINE FOR ORAL ADMINISTRATION
ABSTRACT
The present invention relates to a stable powder composition of pilocarpine for oral administration. In particular, the present invention relates to a reconstitutable powder composition for oral liquid formul...
The present invention relates to an improved process for the preparation of Remogliflozin Remogliflozin etabonate or pharmaceutically acceptable salt solvate hydrate thereof. The present invention relates to an improved process for preparation of Remogliflozin etabonate or pharmaceutically acceptable salt solvat...
ABSTRACT
HIGH GRADE REMOGLIFLOZIN ETABONATE AND AN IMPROVED PROCESS FOR ITS PREPARATION
The present invention provides a high grade Remogliflozin composition that comprises Remogliflozin or Remogliflozin prodrug or pharmaceutically acceptable salt thereof, and not more than 1% impurity. The invention also prov...
The invention relates to a stable pharmaceutical composition comprising remogliflozin or salt or ester thereof, and vildagliptin or salt thereof. In particular disclosed is a pharmaceutical composition comprising a first portion and a second portion, wherein said first portion comprises granules of remogliflozin or ...
The present invention relates to a stable suspension aerosol composition for inhalation comprising glycopyrronium or its pharmaceutical acceptable salt, HFA propellant and one or more pharmaceutically acceptable excipients, to be delivered by pressurized metered dose inhalers (MDIs) for pulmonary administration. The...
The present invention relates to an inhalable fixed dose dry powder
composition comprising glycopyrronium or its pharmaceutically acceptable salt,
formoterol or its pharmaceutically acceptable salt and fluticasone, or a
pharmaceutically acceptable salt or ester thereof, such as fluticasone propionate.
Preferably...
The present invention relates to pharmaceutical composition comprising Remogliflozin or pharmaceutically acceptable salt, ester or derivatives thereof in combination with one or more anti-hyperglycemic agent. In particular, the present invention relates to pharmaceutical composition comprising combination of Remogli...
Abstract
The present invention relates to process for preparing lifitegrast.
The present invention relates to process for the preparation of dydrogesterone.
The present invention relates to a process for the preparation of brivaracetam and salts thereof. The present invention provides process for the preparation of brivaracetam and salts thereof with high chiral purity.
The present invention relates to a process for the preparation of valbenazine and salts thereof.
The present invention relates to an immediate release oral formulation of remogliflozin or pharmaceutically acceptable salts thereof administered in patients in need thereof for the treatment of diabetes mellitus. The present invention further relates to a pharmaceutical formulation comprising synergistic combinatio...
The present invention relates to pharmaceutically acceptable formulations comprising oxalate salts of Teneligliptin and solvates thereof. Also provided are combinations with biguanides and use of said pharmaceutically acceptable formulations for the management of glucose metabolism disorders.
The present invention relates to pharmaceutically acceptable formulations comprising oxalate salts of Teneligliptin and solvates thereof. Also provided are combinations with biguanides and use of said pharmaceutically acceptable formulations for the management of glucose metabolism disorders.
The invention relates to a pharmaceutical composition comprising remogliflozin or pharmaceutically acceptable salt or ester thereof and metformin or pharmaceutically acceptable salt thereof. In particular it relates to an immediate release pharmaceutical composition comprising: (a) remogliflozin or pharmaceuticall...
The invention relates to an immediate release pharmaceutical composition comprising remogliflozin or pharmaceutically acceptable salt or ester thereof and a pharmaceutically acceptable excipient. In particular it relates to an immediate release pharmaceutical composition comprising: (A) an intra granular portion co...
STABLE PHARMACEUTICAL LIQUID COMPOSITION OF SOLIFENACIN
ABSTRACT
The present invention relates to a stable pharmaceutical liquid suspension composition for oral administration of solifenacin or its pharmaceutically acceptable salt, comprising (a) a complex between solifenacin or its pharmaceutically acceptable sal...
A topical pharmaceutical composition comprises adapalene or a pharmaceutical acceptable salt thereof and minocycline or a pharmaceutical acceptable salt thereof. The composition is for topical application and used to treat acne.
The present invention relates to a pharmaceutical foam composition comprising a corticosteroid and a Vitamin D analogue for topical administration to a patient in need thereof, such as for the treatment of plaque psoriasis. The present invention also relates to a process for preparing the composition and a suitable ...
The present invention relates to a topical pharmaceutical composition comprising luliconazole, or a pharmaceutically acceptable salt thereof. The topical compositions described herein are useful for the treatment of skin disorders, such as onychomycosis.
The invention relates to a pharmaceutical composition comprising a combination of lobeglitazone or pharmaceutically acceptable salt thereof and one or more antidiabetic agent. In particular, the invention relates to a pharmaceutical composition comprising combination of lobeglitazone sulfate and glimepiride. The pha...
PHARMACUTICAL COMPOSITION COMPRISING REMOGLIFLOZIN ETABONATE, METFORMIN HYDROCHLORIDE AND TENELIGLIPTIN
The present invention relates to pharmaceutical composition comprising remogliflozin or pharmaceutically acceptable salt, ester or derivatives thereof in combination with one or more anti-hyperglycemic agent. In...
ABSTRACT
PHARMACEUTICAL COMPOSITION COMPRISING ITRACONAZOLE
The invention relates to a stable solid oral pharmaceutical composition comprising itraconazole which provides reduction in pill burden in the treatment of fungal infections, including superficial infections, such as onychomycosis, as well as systemic...
ABSTRACT
Pharmaceutical Composition Comprising Lobeglitazone Sulfate and Metformin Hydrochloride
The invention relates to a pharmaceutical composition comprising a combination of lobeglitazone or pharmaceutically acceptable salt thereof and one or more antidiabetic agent. In particular, the invention relates t...
The present invention relates to a sustained release composition comprising one or more water soluble salt(s) of ruxolitinib, and a means for controlling release of ruxolitinib, the means for controlling release of ruxolitinib are one or more hydrophobic substance(s) such as one or more wax, one or more lipid and on...
The present invention is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, which are useful as CBL-b inhibitors, processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment or prevention of ...
Described herein are stable solid oral capsule dosage form comprising dabigatran etexilate or pharmaceutically acceptable salt and at least one pharmaceutically acceptable excipient, wherein said dosage form has controlled and reduced levels of N-nitroso dabigatran (NDAB). Also, disclosed are methods of manufacturin...
Copyrights
Registered Trademarks
[Class : 5] Pharmaceutical, Medicinal And Ayurvedic Preparations And Substances, Dietetic Food And Substances Adapted For Medical Use, Dietary Supplements For Humans, Nutritional Supplements, Nutraceutical Preparations For Therapeutic Or Medical Purposes, Nutraceuticals For Use As Dietary Supplements
[Class : 5] Pharmaceutical, Medicinal And Ayurvedic Preparations And Substances, Dietetic Food And Substances Adapted For Medical Use, Dietary Supplements For Humans, Nutritional Supplements, Nutraceutical Preparations For Therapeutic Or Medical Purposes, Nutraceuticals For Use As Dietary Supplements
[Class : 5] Pharmaceutical, Medicinal And Ayurvedic Preparations And Substances, Dietetic Food And Substances Adapted For Medical Use, Dietary Supplements For Humans, Nutritional Supplements, Nutraceutical Preparations For Therapeutic Or Medical Purposes, Nutraceuticals For Use As Dietary Supplements
View +2506 more Brands for Glenmark Pharmaceuticals Limited.
Charges
09 June 2008
Bank Of India
170 Crore
23 September 2004
State Bank Of India
10 Crore
21 May 1985
Bank Of India
890 Crore
16 January 2009
Central Bank Of India
150 Crore
12 September 2007
The Hongkong And Shanghai Banking Corporation Limited
200 Crore
18 June 2009
Axis Bank Limited
75 Crore
29 July 2009
Bank Of India
60 Crore
12 September 2007
The Hongkong And Shanghai Banking Corporation Limited
200 Crore
25 November 2004
State Bank Patiala
25 Crore
23 September 2004
State Bank Of Patiala
10 Crore
02 April 2004
State Bank Of Patiala
15 Crore
10 May 2005
State Bank Of India
50 Crore
03 August 2004
State Bank Of Indai
50 Crore
10 May 2004
Idbi Bank Ltd.
25 Crore
23 September 2004
State Bank Of India
0
09 June 2008
Bank Of India
0
21 May 1985
Bank Of India
0
12 September 2007
The Hongkong And Shanghai Banking Corporation Limited
0
18 June 2009
Axis Bank Limited
0
12 September 2007
The Hongkong And Shanghai Banking Corporation Limited
0
23 September 2004
State Bank Of Patiala
0
10 May 2004
Idbi Bank Ltd.
0
16 January 2009
Central Bank Of India
0
03 August 2004
State Bank Of Indai
0
02 April 2004
State Bank Of Patiala
0
25 November 2004
State Bank Patiala
0
29 July 2009
Bank Of India
0
10 May 2005
State Bank Of India
0
23 September 2004
State Bank Of India
0
09 June 2008
Bank Of India
0
21 May 1985
Bank Of India
0
12 September 2007
The Hongkong And Shanghai Banking Corporation Limited
0
18 June 2009
Axis Bank Limited
0
12 September 2007
The Hongkong And Shanghai Banking Corporation Limited
0
23 September 2004
State Bank Of Patiala
0
10 May 2004
Idbi Bank Ltd.
0
16 January 2009
Central Bank Of India
0
03 August 2004
State Bank Of Indai
0
02 April 2004
State Bank Of Patiala
0
25 November 2004
State Bank Patiala
0
29 July 2009
Bank Of India
0
10 May 2005
State Bank Of India
0
Documents
Form DPT-3-04042021_signed
Shareholders-MGT_7_validated_R72333883_GLENMARK_20201130162924.xlsm
Form MGT-7-27112020_signed
Optional Attachment-(2)-26112020
Optional Attachment-(3)-26112020
Optional Attachment-(1)-26112020
Copy of MGT-8-26112020
Form DIR-12-23112020_signed
Evidence of cessation;-23112020
Form MGT-14-13112020-signed
Form AOC-4(XBRL)-29102020_signed
Form MGT-14-28102020_signed
XBRL financial statements duly authenticated as per section 134 (including Board's report,auditor's report and other documents)-28102020
Optional Attachment-(1)-28102020
XBRL document in respect Consolidated financial statement-28102020
Optional Attachment-(1)-26102020
Copy(s) of resolution(s) along with copy of explanatory statement under section 173-26102020
Form DIR-12-20102020_signed
Optional Attachment-(1)-19102020
Form MGT-15-14102020_signed
Form ADT-1-13102020_signed
Copy of written consent given by auditor-13102020
Copy of resolution passed by the company-13102020
Form DPT-3-12092020-signed
Declaration of the appointee director, Managing director, in Form No. DIR-2;-11092020
Form DIR-12-11092020_signed
Optional Attachment-(2)-11092020
-02082020
Optional Attachment-(2)-02082020
Optional Attachment-(1)-02082020
